Vetoquinol SA
PAR:VETO

Watchlist Manager
Vetoquinol SA Logo
Vetoquinol SA
PAR:VETO
Watchlist
Price: 76.6 EUR 0.26% Market Closed
Market Cap: 910m EUR
Have any thoughts about
Vetoquinol SA?
Write Note

Vetoquinol SA
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vetoquinol SA
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Vetoquinol SA
PAR:VETO
Cash from Operating Activities
€85.9m
CAGR 3-Years
-3%
CAGR 5-Years
18%
CAGR 10-Years
10%
Sanofi SA
PAR:SAN
Cash from Operating Activities
€8.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ipsen SA
PAR:IPN
Cash from Operating Activities
€902.5m
CAGR 3-Years
3%
CAGR 5-Years
10%
CAGR 10-Years
17%
Virbac SA
PAR:VIRP
Cash from Operating Activities
€198.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boiron SA
PAR:BOI
Cash from Operating Activities
€42.6m
CAGR 3-Years
8%
CAGR 5-Years
-9%
CAGR 10-Years
-7%
Medincell SA
PAR:MEDCL
Cash from Operating Activities
-€11.9m
CAGR 3-Years
1%
CAGR 5-Years
6%
CAGR 10-Years
N/A
No Stocks Found

Vetoquinol SA
Glance View

Market Cap
906.5m EUR
Industry
Pharmaceuticals

Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.

VETO Intrinsic Value
84.87 EUR
Undervaluation 10%
Intrinsic Value
Price

See Also

What is Vetoquinol SA's Cash from Operating Activities?
Cash from Operating Activities
85.9m EUR

Based on the financial report for Jun 30, 2024, Vetoquinol SA's Cash from Operating Activities amounts to 85.9m EUR.

What is Vetoquinol SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
10%

Over the last year, the Cash from Operating Activities growth was -19%. The average annual Cash from Operating Activities growth rates for Vetoquinol SA have been -3% over the past three years , 18% over the past five years , and 10% over the past ten years .

Back to Top